Knowledge Library
WuXi Biology GPCR Cell Lines and Assays
Immuno-Oncology Platform to Enable Discovery from Target to Drug
Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
Optimizing Drug Discovery Pipelines with Biophysical Methods
Novel Strategies to Accelerate Discovery of Translatable Therapeutic Targets
Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.
Validation of GVHD in mouse model for preclinical efficacy screen
AACR Annual meeting 2021 Na Xu, Ya Zhang, Rou Xie, Lijun Jia, Yingying Cai, Qing Lin Oncology and Immunology Unit, WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China Background Bone marrow transplantation has been successfully and widely used to treat diseases such as leukemia and lymphomas. However, the complication Graft …Read More >
Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer
AACR Annual meeting 2021 Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec, Shanghai, China; 2 WuXi AppTec, Jiangsu, China Corresponding Author: Qunsheng Ji. Email: ji_qunsheng@wuxiapptec.com Background Many cancer types are driven by specific gene aberrances, like gene fusions, mutations and copy number changes. It has led to …Read More >
Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics
AACR Annual meeting 2021 Ting Ni, Zhixiang Zhang, Xuzhen Tang, Hui Qi, Jingying Zhang, Ke Mao, Wenting Shi, Qingyang Gu, Qunsheng Ji WuXi AppTec, Suzhou, China Abstract Recent advances in cancer biology and diagnosis are providing more targeted approaches to treat cancers. Therapy targeting the specific oncogenic driver could inhibit tumor progression and helps to …Read More >
